2026-10-10T19:14:36Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33979783 2026-09-24T04:43:17Z category_388 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Conditional myeloid-specific deletion of Ube2n hinders YUMM1.7 melanoma growth.pdf Kelsie Schiavone (9188440) Adam Pecoraro (18223038) Afsa Khawar (21553727) Kathleen Zhang (25102141) Vaibhav Jain (184214) Simon Gregory (4725282) Daniel T. Starczynowski (9593606) Jennifer Y. Zhang (3952289) Oncology and Carcinogenesis not elsewhere classified macrophage melanoma myeloid cell SPP1 Ube2n <p>The role of UBE2N in myeloid cell-mediated immune suppression in cancer remains undefined. Here, we examined the function of UBE2N in myeloid cell-mediated tumor progression using a temporally inducible myeloid-specific knockout model (LysM^CreERUbe2n^fl/fl). Temporally induced deletion of Ube2n in myeloid cells (Ube2n^MyeKO) significantly hindered growth of YUMM1.7 melanoma. This was accompanied by reduced myeloid cell burden within the tumor microenvironment. We observed altered abundance of PD-1, PD-L1, and SPP1 in the Ube2n^MyeKO tumor microenvironment at the tissue level. In vitro analysis showed that knock-in expression of a catalytically deficient UBE2N^C87S mutant in bone marrow-derived macrophages (BMDMs) markedly decreased expression of Spp1. We observed decreased SPP1 secretion in Ube2n^MyeKO BMDM-conditioned media (CM). Treatment with Ube2n^MyeKO BMDM-CM decreased co-expression of PD-1, TIM-3, and LAG-3 on chronically stimulated T cells. Antibody-mediated neutralization of SPP1 in Ube2n^MyeWT BMDM-CM decreased PD-1 expression on CD8+ T cells. Together, these findings suggest a role for myeloid UBE2N in YUMM1.7 progression.</p> 2026-09-24T04:43:17Z Dataset Dataset 10.3389/fonc.2026.1932270.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Conditional_myeloid-specific_deletion_of_Ube2n_hinders_YUMM1_7_melanoma_growth_pdf/33979783 CC BY 4.0